

ASX ANNOUNCEMENT

22 January 2024

Three Difficult to Treat DurAVR™ Valve-in-Valve Patients Completed under Health Canada's Special Access Program

Anteris Technologies Ltd (ASX: AVR), a structural heart company committed to designing, developing, and commercialising innovative medical devices, is pleased to announce the successful completion of three new valve-in-valve (ViV) cases using DurAVR™, a first-in-class biomimetic transcatheter heart valve.

These are the 4th- 6th patients treated with DurAVR™ under Health Canada's special access program (SAP) which allows health care professionals to access unlicensed medical devices, such as DurAVR™, for emergency use when conventional therapies have failed, are unavailable, or are unsuitable to treat a patient. The approval is based on multiple factors including past patient outcomes, safety data and physician support.

Transcatheter ViV replacement is performed by implanting a transcatheter heart valve within a failing bioprosthetic aortic valve. The transcatheter ViV operation is a less invasive procedure compared with reoperative surgical aortic valve replacement.

Dr Anita Asgar, Institut de Cardiologie de Montreal, commented, "The challenges we face as clinicians is the need to preserve coronary access, but these are also patients who are also reasonably active, and we need to give them a good haemodynamic result, we need to really improve their symptoms so they can have a good quality of life".

Dr Asgar, who performed the procedures, stated, "As a clinician, it's a great opportunity to have access to a technology that may help us with what is probably going to be a tsunami of valve-in-valve procedures that we are going to have to do".

"These patients are in a challenging situation and are in need of a better option than what is commercially available. DurAVR™ delivered an outstanding result with meaningful patient benefits".

Wayne Paterson CEO commented, "With an increasing number of bioprosthetic valves failing in patients it's important that we study the effects of DurAVR™ in this patient population to better understand if the best-in-class results we see in newly treated aortic stenosis is also seen in this difficult to treat population. We are pleased with the results to date and will continue to study this group who have limited treatment options today".

ENDS



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVR™, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR™ THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR™ THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR™ Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR™ THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations (US)

Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269

Investor Relations

investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200

Website www.anteristech.com
Twitter @AnterisTech
Facebook www.facebook.com/AnterisTech
LinkedIn <https://www.linkedin.com/company/anteristech>

